BR112018067851A2 - composições e métodos para o tratamento de artrite reumatoide - Google Patents

composições e métodos para o tratamento de artrite reumatoide

Info

Publication number
BR112018067851A2
BR112018067851A2 BR112018067851A BR112018067851A BR112018067851A2 BR 112018067851 A2 BR112018067851 A2 BR 112018067851A2 BR 112018067851 A BR112018067851 A BR 112018067851A BR 112018067851 A BR112018067851 A BR 112018067851A BR 112018067851 A2 BR112018067851 A2 BR 112018067851A2
Authority
BR
Brazil
Prior art keywords
rheumatoid arthritis
treatment
compositions
methods
improvement
Prior art date
Application number
BR112018067851A
Other languages
English (en)
Inventor
Boddy Alexander
Bauer Deborah
VAN HOOGSTRATEN Hubert
Van Adelsberg Janet
Parrino Janie
Graham Neil
Patel Rahul
Lin Yong
Original Assignee
Regeneron Pharma
Sanofi Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by Regeneron Pharma, Sanofi Biotechnology filed Critical Regeneron Pharma
Publication of BR112018067851A2 publication Critical patent/BR112018067851A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção refere-se ao uso de um anticorpo do receptor de anti-il6 em monoterapia para o tratamento da artrite reumatoide e para a melhora da função física e da qualidade de vida de um indivíduo que sofre de artrite reumatoide.
BR112018067851A 2016-03-07 2017-03-07 composições e métodos para o tratamento de artrite reumatoide BR112018067851A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664 2016-05-20
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis

Publications (1)

Publication Number Publication Date
BR112018067851A2 true BR112018067851A2 (pt) 2019-02-05

Family

ID=58387910

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018067851A BR112018067851A2 (pt) 2016-03-07 2017-03-07 composições e métodos para o tratamento de artrite reumatoide

Country Status (18)

Country Link
US (1) US20190100585A1 (pt)
EP (1) EP3426295A1 (pt)
JP (2) JP7166925B2 (pt)
KR (2) KR20180114955A (pt)
CN (1) CN109069642A (pt)
AU (2) AU2017229364A1 (pt)
BR (1) BR112018067851A2 (pt)
CA (1) CA3016880A1 (pt)
CL (1) CL2018002559A1 (pt)
CR (1) CR20180465A (pt)
EA (1) EA201892005A1 (pt)
IL (2) IL308539A (pt)
MX (2) MX2018010815A (pt)
PH (1) PH12018501894A1 (pt)
SG (2) SG11201807614SA (pt)
TN (1) TN2018000312A1 (pt)
TW (3) TWI747885B (pt)
WO (1) WO2017155990A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN111110842B (zh) * 2017-11-30 2020-12-11 百奥泰生物制药股份有限公司 一种治疗il-6相关疾病的人源化抗体的液体制剂
MX2021002422A (es) 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
CA3128212A1 (en) 2019-01-31 2020-08-06 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
EP3959240A1 (en) 2019-04-24 2022-03-02 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2868614A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
PL2041177T3 (pl) 2006-06-02 2012-09-28 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
US20160280782A1 (en) * 2013-11-22 2016-09-29 Sanofi Biotechnology Compositions for the treatment of rheumatoid arthritis and methods of using same

Also Published As

Publication number Publication date
EA201892005A1 (ru) 2019-02-28
CR20180465A (es) 2019-03-04
EP3426295A1 (en) 2019-01-16
US20190100585A1 (en) 2019-04-04
TW202239767A (zh) 2022-10-16
SG10202012182YA (en) 2021-01-28
CN109069642A (zh) 2018-12-21
JP2023011711A (ja) 2023-01-24
SG11201807614SA (en) 2018-10-30
KR20230093522A (ko) 2023-06-27
TWI747885B (zh) 2021-12-01
TN2018000312A1 (en) 2020-01-16
IL261515B2 (en) 2024-04-01
JP2019507775A (ja) 2019-03-22
AU2017229364A1 (en) 2018-10-25
KR20180114955A (ko) 2018-10-19
PH12018501894A1 (en) 2019-05-15
IL261515A (en) 2018-10-31
WO2017155990A1 (en) 2017-09-14
CA3016880A1 (en) 2017-09-14
NZ746988A (en) 2023-10-27
JP7166925B2 (ja) 2022-11-08
IL261515B1 (en) 2023-12-01
MX2018010815A (es) 2019-01-10
TW202419103A (zh) 2024-05-16
IL308539A (en) 2024-01-01
CL2018002559A1 (es) 2019-03-01
MX2023014841A (es) 2024-01-15
TWI819435B (zh) 2023-10-21
AU2024203011A1 (en) 2024-07-11
TW201808993A (zh) 2018-03-16

Similar Documents

Publication Publication Date Title
BR112018067851A2 (pt) composições e métodos para o tratamento de artrite reumatoide
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
CR20180013A (es) Anticuerpos anti-tau y métodos de uso.
CL2017000590A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2017002401A1 (es) Anticuerpos contra icos
CR20190271A (es) Anticuerpos antitau y métodos de uso
CR20160362A (es) Anticuerpos anti-jagged1 y metodos de uso
BR112016026950A2 (pt) composições de rnai para angiotensinogênio (agt) e métodos de uso das mesmas
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
CR20170131A (es) Anticuerpos anti-her2 e inmunoconjugados
BR112017005517A2 (pt) anticorpos antiage para o tratamento de inflama-ção e de transtornos autoimunes
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2019006330A (es) Anticuerpos anti-tau y metodos de uso.
MX2020011993A (es) Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
BR112017022073A2 (pt) método para purificação de proteína
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.
EA201792312A1 (ru) Конструкции на основе калихеамицина и способы их применения
BR112018010596A2 (pt) anticorpos para cgrp e usos dos mesmos
CL2017001172A1 (es) Anticuerpos anti-interleukin-33 y sus usos
EA201892257A1 (ru) Анти-cd3 антитела и способы применения

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]